RenovaRo Inc. Changes Fiscal Year End

TL;DR

RenovaRo Inc. is changing its fiscal year end to Dec 31, affecting 2024 reporting.

AI Summary

On September 11, 2024, RenovaRo Inc. filed an 8-K report. The filing indicates a change in the company's fiscal year end from June 30 to December 31. This change is effective immediately and will result in a transition period for the fiscal year ending December 31, 2024.

Why It Matters

This change in fiscal year end can impact financial reporting timelines and comparisons with prior periods for investors.

Risk Assessment

Risk Level: low — The filing is a routine administrative change and does not involve significant operational or financial risk.

Key Players & Entities

• RenovaRo Inc. (company) — Registrant
• September 11, 2024 (date) — Date of Report
• December 31 (date) — New Fiscal Year End
• June 30 (date) — Previous Fiscal Year End

FAQ

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar

Filing Documents

• e5928_8-k.htm (8-K) — 33KB
• 0001731122-24-001372.txt ( ) — 205KB
• renb-20240911.xsd (EX-101.SCH) — 3KB
• renb-20240911_lab.xml (EX-101.LAB) — 33KB
• renb-20240911_pre.xml (EX-101.PRE) — 22KB
• e5928_8-k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On September 11, 2024, Renovaro Inc. (the " Company ") issued a press release. The press release is reproduced below. FOR IMMEDIATE RELEASE RenovaroCube Announces Strategic Offering of Up to 20% Ownership Amsterdam, the Netherlands, September 11, 2024 (NASDAQ: RENB) The Board of Renovaro Inc (RENB) intends to seek strategic investors to acquire up to 20% of Cube, currently a wholly owned subsidiary. This opportunity will be available to all potential investors including current shareholders of RENB. Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology for multi-omics and multi-modal data analysis, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes, beginning with cancer. "Newly raised funds from strategic investors could help accelerate our go-to-market strategy to generate revenue through our innovative open-access AI engine that has the potential to be used by many sources in the private sector and by large health care systems as well as advancing our own product pipeline beginning with a blood test to detect recurrence of certain cancers within a few days of beginning treatment," said Dr. Henk Vietor, the Managing Director of Cube. Cube expects to use the proceeds from the offering primarily to advance Cube's platform. Renovaro, Inc, through RenovaroBio, also remains focused on advancing its patented cancer vaccine targeting difficult to treat solid tumors such as pancreatic, head and neck, liver and others. We believe advancing the Cube pipeline has the potential to create a multiplier effect towards a vertically integrated approach to cancer from early diagnosis, to selection of treatments more likely to succeed, early detection of recurrence and, ultimately, new therapies. Subscription terms are to be determined with potential in

Forward-Looking Statements

Forward-Looking Statements release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as "believes," "plans," "expects," "aims," "intends," "potential," or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro's most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This press release is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. For media inquiries, please contact: karen@renovarocube.com Source: Renovaro Inc. The information included in this Item 8.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that Section or

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO INC. By: /s/ Mark Dybul, M.D. Name: Mark Dybul Title: Chief Executive Officer Date: September 11, 2024

View Full Filing

View this 8-K filing on SEC EDGAR